Last reviewed · How we verify
Pyrimethamine/Sulfadiazine
Pyrimethamine and sulfadiazine work synergistically to inhibit folate metabolism in parasites and bacteria, blocking nucleotide synthesis and preventing microbial replication.
Pyrimethamine and sulfadiazine work synergistically to inhibit folate metabolism in parasites and bacteria, blocking nucleotide synthesis and preventing microbial replication. Used for Toxoplasmosis, including cerebral toxoplasmosis in immunocompromised patients, Toxoplasma gondii infection prophylaxis and treatment.
At a glance
| Generic name | Pyrimethamine/Sulfadiazine |
|---|---|
| Also known as | Pyrimethamine = Malocide®, Sulfadiazine = Adiazine® |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antiparasitic/Antimicrobial combination |
| Target | Dihydrofolate reductase (pyrimethamine); Dihydropteroate synthase (sulfadiazine) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Pyrimethamine inhibits dihydrofolate reductase in parasites, while sulfadiazine inhibits bacterial folate synthesis by blocking dihydropteroate synthase. Together, they create a dual blockade of the folate pathway, making them particularly effective against Toxoplasma gondii and other intracellular pathogens. This combination is the standard treatment for toxoplasmosis, especially in immunocompromised patients.
Approved indications
- Toxoplasmosis, including cerebral toxoplasmosis in immunocompromised patients
- Toxoplasma gondii infection prophylaxis and treatment
Common side effects
- Rash
- Bone marrow suppression
- Nausea
- Vomiting
- Crystalluria
- Hepatotoxicity
Key clinical trials
- The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System (NA)
- Efficacy of Symprove Probiotics in Coeliac Disease (NA)
- Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF (NA)
- VCOM Pain Free Research Collaborative (NA)
- Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
- The Effect of The Ten-Session Dual-tDCS On Lower-Limb Performance in Sub- Acute and Chronic Stroke (NA)
- Acute Effect of the Thoraco-abdominal Rebalance Method on Diaphragmatic Function, Respiratory Discomfort, Pulmonary Complications and Hemodynamic Variables in Postoperative Cardiac Surgery Patients (NA)
- Antidandruff Lotion Mediating Microbiome Rebalance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyrimethamine/Sulfadiazine CI brief — competitive landscape report
- Pyrimethamine/Sulfadiazine updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI